Deucravacitinib in Plaque Psoriasis: Laboratory Parameters Through 4 Years of Treatment in the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. J of Skin. 2024;8(6):s419. doi:10.25251/skin.8.supp.419